Detrimental effects of oxidative losses in parkin activity in a model of sporadic Parkinson's disease are attenuated by restoration of PGC1alpha

Neurobiology of Disease

Volumn 93, Issue , 2016, Pages 115-120

  Siddiqui, Almas ^a   Rane, Anand ^a   Rajagopalan, Subramanian ^a   Chinta, Shankar J ^a   Andersen, Julie K ^a  

^a Buck Research Institute for Research on Aging   (United States)

Author keywords

Mitochondrial dysfunction; Monoamine oxidase B; Parkin; Parkinson's disease; PGC 1 ; Reactive oxygen species

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PPARGC1A PROTEIN, HUMAN; PPARGC1A PROTEIN, MOUSE; PROTEASOME; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; FEMALE; MALE; MOUSE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA PARS COMPACTA; ANIMAL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MITOCHONDRION; PHYSIOLOGY; SUBSTANTIA NIGRA; TRANSGENIC MOUSE;

ANIMALS; DOPAMINERGIC NEURONS; HUMANS; MICE, TRANSGENIC; MITOCHONDRIA; OXIDATIVE STRESS; PARKINSON DISEASE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA COACTIVATOR 1-ALPHA; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; UBIQUITIN-PROTEIN LIGASES;

EID: 84968756394     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.05.009     Document Type: Article

References (21)

1. Chung K.K., et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004.
2. Cookson M.R. Neurodegeneration: how does parkin prevent Parkinson's disease?. Curr. Biol. 2003, 13:R522-R524.
3. Decressac M., et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E1817-E1826. 10.1073/pnas.1305623110.
4. Kitada T., et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism [see comments]. Nature 1998, 392:605-608.
5. Kumar M.J., Andersen J.K. Perspectives on MAO-B in aging and neurological disease: where do we go from here?. Mol. Neurobiol. 2004, (in press).
6. Langston W. Astrocytes, brain aging, and neurodegeneration. Neurobiol. Aging 1996, 17:483-485. (discussion 488-490).
7. Langston J.W., Irwin I., DeLanney L.E. The biotransformation of MPTP and disposition of MPP+: the effects of aging. Life Sci. 1987, 40:749-754.
8. LaVoie M.J., Ostaszewski B.L., Weihofen A., Schlossmacher M.G., Selkoe D.J. Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 2005, 11:1214-1221. 10.1038/nm1314.
9. Liang H., et al. Whole body overexpression of PGC-1alpha has opposite effects on hepatic and muscle insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E945-E954. 10.1152/ajpendo.90292.2008.
10. Mallajosyula J.K., et al. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS ONE 2008, 3.
11. Meng F., et al. Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation. Mol. Neurodegener. 2011, 6:34. 10.1186/1750-1326-6-34.
12. Shin J.H., et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011, 144:689-702. 10.1016/j.cell.2011.02.010.
13. Siddiqui A., Mallajosyula J.K., Rane A., Andersen J.K. Ability to delay neuropathological events associated with astrocytic MAO-B increase in a Parkinsonian mouse model: implications for early intervention on disease progression. Neurobiol. Dis. 2010, 40:444-448. (doi:S0969-9961(10)00228-7 [pii] 10.1016/j.nbd.2010.07.004).
14. Siddiqui A., Hanson I., Andersen J.K. Mao-B elevation decreases parkin's ability to efficiently clear damaged mitochondria: protective effects of rapamycin. Free Radic. Res. 2012, 46:1011-1018. 10.3109/10715762.2012.662277.
15. Siddiqui A., et al. Selective binding of nuclear alpha-synuclein to the PGC1alpha promoter under conditions of oxidative stress may contribute to losses in mitochondrial function: implications for Parkinson's disease. Free Radic. Biol. Med. 2012, 53:993-1003. 10.1016/j.freeradbiomed.2012.05.024.
16. Siddiqui A., et al. Mitochondrial quality control via the PGC1alpha-TFEB signaling pathway is compromised by parkin Q311X mutation but independently restored by rapamycin. J. Neurosci. 2015, 35:12833-12844. 10.1523/JNEUROSCI.0109-15.2015.
17. Wang C., et al. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum. Mol. Genet. 2005, 14:3885-3897. (doi:ddi413 [pii]10.1093/hmg/ddi413).
18. Winklhofer K.F., Henn I.H., Kay-Jackson P.C., Heller U., Tatzelt J. Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J. Biol. Chem. 2003, 278:47199-47208.
19. Wong E.S., et al. Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations. J. Biol. Chem. 2007, 282:12310-12318. 10.1074/jbc.M609466200.
20. Yao D., et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10810-10814. 10.1073/pnas.0404161101.
21. Zheng B., et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med. 2010, 2. 10.1126/scitranslmed.3001059.